COVID-19 caused various symptomatic manifestations in humans. Viral reservoirs are found at naso-oropharyngeal areas and challenge the dentist to reduce the virus using antiseptics, such as PVP-I and Iota-carrageenan (IC). Clinical trials of the above regimes on COVID-19 patients have never been carried out. Aim: To evaluate subjective clinical symptoms in COVID-19 patients after using PVP-I 1% mouthwash and IC nasal spray. Method. A single-blind randomized clinical trial was done in Wisma Atlet emergency hospital. Recruitment of subjects obtains from those who fulfilled the inclusion criteria under informed consent. Eighty-nine subjects who received standard drug of COVID-19 were then divided into Group-A that received PVP-I for 14 days, IC for seven days, and Group-B, who did not receive. Data collections were recorded at the beginning and end of observation for 17 subjective clinical symptoms. Chi- square was used to find the correlation among groups. Results. Male, 19-30 y.o were dominant in both groups. The mean duration of PVP-I and IC used was 5.6 and 5.51 days, respectively. The five frequent symptoms were anosmia, dry cough, fever, slimed cough, and headache. On the 8th day, there was a significant difference in symptoms between-group in dry cough (P=0.003), fever (P=0.024), and sore throat (P=0.001), and dysgeusia (P=0.042) on the 14th day. Conclusions. Using PVP-I mouthwash six times/day and iota-carrageenan nasal spray three times/day for 5 to 6 days may reduce several subjective clinical symptoms.